Oxford Biomedica

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. Our technology platforms include a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, we have a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb and Immune Design Corp.
Company Growth (employees)
Oxford, GB
Size (employees)
247 (est)+7%
Oxford Biomedica was founded in 1995 and is headquartered in Oxford, GB

Oxford Biomedica Office Locations

Oxford Biomedica has an office in Oxford
Oxford, GB (HQ)
Transport Way

Oxford Biomedica Data and Metrics

Oxford Biomedica Financial Metrics

Oxford Biomedica's revenue was reported to be £27.8 m in FY, 2016 which is a 75% increase from the previous period.

Revenue (FY, 2016)

27.8 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

15.9 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(16.6 m)

Market capitalization (19-Sep-2017)

259.4 m

Closing share price (19-Sep-2017)


Cash (31-Dec-2016)

15.3 m
Oxford Biomedica's current market capitalization is £259.4 m.
GBPFY, 2013FY, 2014FY, 2015FY, 2016


5.4 m13.6 m15.9 m27.8 m

Revenue growth, %


Cost of goods sold

1.1 m4.4 m5.8 m11.8 m

Gross profit

4.2 m9.2 m10.1 m15.9 m
GBPFY, 2013FY, 2014FY, 2015FY, 2016


2.2 m14.2 m9.4 m15.3 m

Accounts Receivable

1.7 m4 m8.5 m4.9 m

Current Assets

6.9 m22.8 m25.7 m27.4 m


4.1 m8.9 m24.4 m28.2 m
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Cash From Operating Activities

(11 m)(6 m)(13.1 m)(5.1 m)

Cash From Financing Activities

23.6 m25 m17.5 m

Income Taxes Paid

1.7 m2.1 m4 m3.7 m
GBPY, 2016


112.5 k

Financial Leverage

4.5 x
Show all financial metrics

Oxford Biomedica Operating Metrics

Oxford Biomedica's Clinical Programs was reported to be 114 in FY, 2015
FY, 2015

Patents Issued


Clinical Programs

Show all operating metrics

Oxford Biomedica Market Value History

Oxford Biomedica's employees are reported to be approximately 50% female and 50% male.
Show all human capital metrics

Traffic Overview of Oxford Biomedica

Oxford Biomedica Online and Social Media Presence

Oxford Biomedica News and Updates

Biotechs ink gene therapy deal to treat inherited and rare diseases

Oxford BioMedica has teamed up with fellow UK biotech firm Orchard Therapeutics to develop gene therapies for rare diseases. Orchard will lead the global clinical development and commercialisation of these collaboration programmes in Europe and the US. Oxford BioMedica has picked up a 1.95 per…

Oxford Biomedica Company Life and Culture

You may also be interested in